Unconventional treatment options in severe asthma: An overview

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 3, 2011, Pages 387-399

  Banh, Hoan Linh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AUROTHIOMALATE; AZATHIOPRINE; AZITHROMYCIN; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN; DAPSONE; ENOXAPARIN; FLUCONAZOLE; FUROSEMIDE; GOLIMUMAB; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; METHOTREXATE; OMALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; ASTHMA; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE INDUCED ASTHMA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEMOLYSIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; MOUTH ULCER; NAUSEA; NEPHROTIC SYNDROME; PRACTICE GUIDELINE; PROTEINURIA; PRURITUS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEVERE ASTHMA; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; UTERINE CERVIX CARCINOMA;

EID: 80355148549     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j37s36     Document Type: Review

References (181)

1. World health organization. chronic respiratory disease - asthma. http://www.who.int.login.ezproxy.library.ualberta.c a/respiratory/asthma/definition/en/. Accessed September 18, 2010.
2. Global strategy for asthma management and prevention. Global initiative for asthma (GINA); 2008.
3. Asthma society of canada. asthma facts and statistics. http://www.asthma.ca/corp/newsroom/pdf/asthmast ats.pdf Accessed September 23, 2010.
4. Statistics canada. table 102-0551 - deaths and mortality rate, by selected grouped causes, age group and sex, canada, annual (table), CANSIM (database). Accessed September 28, 2010.
5. Asthma society of canada. asthma facts and statistics. http://www.asthma.ca/corp/newsroom/pdf/asthmast ats.pdf Accessed September 23, 2010.
6. National asthma education and prevention program: Expert panel report III: Guidelines for the diagnosis and management of asthma. [internet]. bethesda., MD: National heart, lung and blood institute, 2007 [Accessed april 2011]. available from [Internet]. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdl n.pdf.
7. Bush A, Menzies-Gow A. Phenotypic differences between pediatric and adult asthma. Proc Am Thorac Soc. 2009 Dec;6(8):712-9.
8. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006 Aug 26;368(9537):780-93.
9. Moore WC, Peters SP. Severe asthma: An overview. J Allergy Clin Immunol. 2006 Mar;117(3):487-494; quiz 495.
10. Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions. american thoracic society. Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51.
11. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: Document presented for the world health organization consultation on severe asthma. J Allergy Clin Immunol. 2010 Nov;126(5):926-38.
12. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med. 1997 Nov 13;337(20):1405-11.
13. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481-8.
14. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol. 2007 Feb;119(2):344-50.
15. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program. J Allergy Clin Immunol. 2007 Feb;119(2):405-13.
16. Ogawa Y, Calhoun WJ. Phenotypic characterization of severe asthma. Curr Opin Pulm Med. 2010 Jan;16(1):48-54.
17. Morjaria JB, Polosa R. Recommendation for optimal management of severe refractory asthma. J Asthma Allergy. 2010 Jul 26;3:43-56.
18. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ. 2009 Feb 24;338:b494.
19. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23.
20. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004 May;23(5):723-9.
21. Polosa R. An overview of chronic severe asthma. Intern Med J. 2008 Mar;38(3):190-8.
22. Polosa R, Benfatto GT. Managing patients with chronic severe asthma: Rise to the challenge. Eur J Intern Med. 2009 Mar;20(2):114-24.
23. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med. 2008 Nov;102(11):1499-510.
24. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 1993 Mar;31 Suppl C:1-9.
25. Oishi K, Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun. 1994 Oct;62(10):4145-4152.
26. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy. Respiration. 1996;63(1):42-48.
27. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: A preliminary report. Allergy Asthma Proc. 2007 Mar-Apr;28(2):194-198.
28. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001 May;119(5):1329-36.
29. Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007 Dec;62(12):1043-9.
30. Cunningham AF, Johnston SL, Julious SA, Lampe FC, Ward ME. Chronic chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J. 1998 Feb;11(2):345-9.
31. Wark PA, Johnston SL, Simpson JL, Hensley MJ, Gibson PG. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J. 2002 Oct;20(4):834-40.
32. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. J Allergy Clin Immunol. 2001 Apr;107(4):595-601.
33. Biscione GL, Corne J, Chauhan AJ, Johnston SL. Increased frequency of detection of chlamydophila pneumoniae in asthma. Eur Respir J. 2004 Nov;24(5):745-9.
34. Chauhan AJ, Inskip HM, Linaker CH, Smith S, Schreiber J, Johnston SL, et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virusinduced asthma in children. Lancet. 2003 Jun 7;361(9373):1939-1944.
35. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2005 Oct 19;(4)(4):CD002997.
36. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials. 2006 Jun;1(2):e11.
37. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest. 2004 Feb;125(2 Suppl):52S,60S; quiz 60S-61S.
38. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006 Apr 13;354(15):1589-1600.
39. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008 Jan 15;177(2):148-55.
40. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest. 2002 Jun;121(6):1782-8.
41. Greenberger PA. Clinical aspects of allergic bronchopulmonary aspergillosis. Front Biosci. 2003 Jan 1;8:s119-27.
42. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009 Mar;135(3):805-26.
43. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev. 2004;(3)(3):CD001108.
44. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000 Mar 16;342(11):756-762.
45. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial. J Allergy Clin Immunol. 2003 May;111(5):952-7.
46. Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc. 2010 May;7(3):237-44.
47. Agarwal R, Gupta D. Severe asthma and fungi: Current evidence. Med Mycol. 2011 Apr;49 Suppl 1:S150-7.
48. Matsuoka H, Niimi A, Matsumoto H, Ueda T, Takemura M, Yamaguchi M, et al. Specific IgE response to trichophyton and asthma severity. Chest. 2009 Apr;135(4):898-903.
49. Niedoszytko M, Chelminska M, Jassem E, Czestochowska E. Association between sensitization to aureobasidium pullulans (pullularia sp) and severity of asthma. Ann Allergy Asthma Immunol. 2007 Feb;98(2):153-6.
50. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: A summary of the evidence. Eur Respir J. 2006 Mar;27(3):615-26.
51. Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The fungal asthma sensitization trial (FAST) study. Am J Respir Crit Care Med. 2009 Jan 1;179(1):11-18.
52. Ward GW Jr, Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA. Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):541-6.
53. Douwes J, Gibson P, Pekkanen J, Pearce N. Noneosinophilic asthma: Importance and possible mechanisms. Thorax. 2002 Jul;57(7):643-8.
54. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: An update. Pharmacol Rev. 1998 Dec;50(4):515-96.
55. Tsai JJ, Wang TF, Wang SR. The inhibitory effect of methotrexate on PAF-induced neutrophil and eosinophil locomotion in asthmatic patients. Asian Pac J Allergy Immunol. 1994 Jun;12(1):65-71.
56. Suarez CR, Pickett WC, Bell DH, McClintock DK, Oronsky AL, Kerwar SS. Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a. J Rheumatol. 1987 Feb;14(1):9-11.
57. Ternowitz T, Bjerring P, Andersen PH, Schroder JM, Kragballe K. Methotrexate inhibits the humanC5a-induced skin response in patients with psoriasis. J Invest Dermatol. 1987 Aug;89(2):192-6.
58. Lammers AM, van de Kerkhof PC, Mier PD. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis. Br J Dermatol. 1987 May;116(5):667-671.
59. Vrugt B, Wilson S, Bron A, Shute J, Holgate ST, Djukanovic R, et al. Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: Effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogeninduced T-cell proliferation. Eur Respir J. 2000 Mar;15(3):478-485.
60. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000;(2)(2):CD000391.
61. Comet R, Domingo C, Larrosa M, Moron A, Rue M, Amengual MJ, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med. 2006 Mar;100(3):411-9.
62. Kon OM, Kay AB. T cells and chronic asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):133-135.
63. Corrigan CJ, Brown PH, Barnes NC, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance in chronic asthma. peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis. 1991 Nov;144(5):1026-32.
64. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med. 1995 Jan 1;181(1):33-40.
65. Leung DY. Steroid-resistant asthma. West J Med. 1995 Oct;163(4):367-368.
66. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 1992 Feb 8;339(8789):324-328.
67. Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax. 1997 May;52(5):447-52.
68. Frew AJ, Plummeridge MJ. Alternative agents in asthma. J Allergy Clin Immunol. 2001 Jul;108(1):3-10.
69. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001;(2)(2):CD002993.
70. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroiddependent asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):509-14.
71. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroiddependent bronchial asthma with cyclosporin. Eur Respir J. 1995 Jul;8(7):1091-9.
72. Ledford DK. Treatment of steroid-resistant asthma. Immunology and Allergy Clinics of North America. 1996 NOV;16(4):777
73. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001;(2)(2):CD002985.
74. Muranaka M, Miyamoto T, Shida T, Kabe J, Makino S, Okumura H, et al. Gold salt in the treatment of bronchial asthma--a double-blind study. Ann Allergy. 1978 Feb;40(2):132-7.
75. Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH. Auranofin in the treatment of steroid dependent asthma: A double blind study. Thorax. 1992 May;47(5):349-54.
76. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. auranofin multicenter drug trial. J Allergy Clin Immunol. 1996 Aug;98(2):317-24.
77. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: An alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol. 1996 May;104 Suppl 1:61-6.
78. Landwehr LP, Jeppson JD, Katlan MG, Esterl B, McCormick D, Hamilos DL, et al. Benefits of highdose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest. 1998 Nov;114(5):1349-56.
79. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol. 1991 May;87(5):976-83.
80. Salmun LM, Barlan I, Wolf HM, Eibl M, Twarog FJ, Geha RS, et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebocontrolled, randomized trial. J Allergy Clin Immunol. 1999 May;103(5 Pt 1):810-5.
81. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987 Feb;79(2):468-72.
82. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human Tcell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol. 1994 Nov;73(2):180-186.
83. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoidreduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):421-6.
84. Jakobsson T, Croner S, Kjellman NI, Pettersson A, Vassella C, Bjorksten B. Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy. 1994 Jul;49(6):413-20.
85. Haque S, Boyce N, Thien FC, O'Hehir RE, Douglass J. Role of intravenous immunoglobulin in severe steroid-dependent asthma. Intern Med J. 2003 Aug;33(8):341-4.
86. Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, et al. A multicenter, randomized, double-blind, placebocontrolled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol. 1999 May;91(2):126-33.
87. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. detection of IgE antibodies to IgA. N Engl J Med. 1986 Feb 27;314(9):560-4.
88. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991 Jul 11;325(2):110-7.
89. Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: Adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008 Mar;121(3):e626-30.
90. Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: A comparison of intravenous immunoglobulins. Postgrad Med. 2010 Sep;122(5):176-84.
91. van Furth R, Gassmann AE, Diesselhoff-Den Dulk MM. The effect of azathioprine (imuran) on the cell cycle of promonocytes and the production of monocytes in the bone marrow. J Exp Med. 1975 Mar 1;141(3):531-46.
92. Levy J, Barnett EV, MacDonald NS, Klinenberg JR, Pearson CM. The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest. 1972 Sep;51(9):2233-8.
93. Liu HN, Wong CK. In vitro immunosuppressive effects of methotrexate and azathioprine on langerhans cells. Arch Dermatol Res. 1997 Jan;289(2):94-7.
94. Gorski A, Korczak-Kowalska G, Nowaczyk M, Paczek L, Gaciong Z. The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology. 1983 Dec;6(4):259-66.
95. Elion GB. The george hitchings and gertrude elion lecture. the pharmacology of azathioprine. Ann N Y Acad Sci. 1993 Jun 23;685:400-7.
96. Hodges NG, Brewis RA, Howell JB. An evaluation of azathioprine in severe chronic asthma. Thorax. 1971 Nov;26(6):734-9.
97. HARTUNG EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis. 1954 Sep;13(3):190-200.
98. Ilfeld D, Kivity S, Feierman E, Topilsky M, Kuperman O. Effect of in vitro colchicine and oral theophylline on suppressor cell function of asthmatic patients. Clin Exp Immunol. 1985 Aug;61(2):360-7.
99. Caner JE. Colchicine inhibition of chemotaxis. Arthritis Rheum. 1965 Oct;8(5):757-64.
100. Malawista SE, Bodel PT. The dissociation by colchicine of phagocytosis from increased oxygen consumption in human leukocytes. J Clin Invest. 1967 May;46(5):786-96.
101. Hoffstein S, Zurier RB, Weissmann G. Mechanisms of lysosomal enzyme release from human leucocytes. III. quantitative morphologic evidence for an effect of cyclic nucleotides and colchicine on degranulation. Clin Immunol Immunopathol. 1974 Nov;3(2):201-17.
102. Gillespie E, Lichtenstein LM. Histamine release from human leukocytes: Studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest. 1972 Nov;51(11):2941-7.
103. Kaliner M. Human lung tissue and anaphylaxis. evidence that cyclic nucleotides modulate the immunologic release of mediators through effects on microtubular assembly. J Clin Invest. 1977 Oct;60(4):951-9.
104. Fish JE, Peters SP, Chambers CV, McGeady SJ, Epstein KR, Boushey HA, et al. An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate asthma. national heart, lung, and blood institute's asthma clinical research network. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1165-71.
105. Newman KB, Mason UG, Buchmeier A, Schmaling KB, Corsello P, Nelson HS. Failure of colchicine to reduce inhaled triamcinolone dose in patients with asthma. J Allergy Clin Immunol. 1997 Feb;99(2):176-8.
106. Adalioglu G, Turktas I, Saraclar Y, Tuncer A. A clinical study of colchicine in childhood asthma. J Asthma. 1994;31(5):361-6.
107. Schwarz YA, Kivity S, Ilfeld DN, Schlesinger M, Greif J, Topilsky M, et al. A clinical and immunologic study of colchicine in asthma. J Allergy Clin Immunol. 1990 Mar;85(3):578-82.
108. Kelly SJ, Uri AJ, Freeland HS, Woods EJ, Schulman ES, Peters SP, et al. Effects of colchicine on IgE-mediated early and late airway reactions. Chest. 1995 Apr;107(4):985-91.
109. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992 Feb;98(2):135-40.
110. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: A possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 1993 Apr;100(4):349-55.
111. Berlow BA, Liebhaber MI, Dyer Z, Spiegel TM. The effect of dapsone in steroid-dependent asthma. J Allergy Clin Immunol. 1991 Mar;87(3):710-5.
112. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91.
113. Fox RI, Kang HI. Mechanism of action of antimalarial drugs: Inhibition of antigen processing and presentation. Lupus. 1993 Feb;2 Suppl 1:S9-12.
114. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol. 1998 Aug;102(2):198-203.
115. Goldstein JA. Hydroxychloroquine for asthma. Am Rev Respir Dis. 1983 Dec;128(6):1100-1.
116. Roberts JA, Gunneberg A, Elliott JA, Thomson NC. Hydroxychloroquine in steroid dependent asthma. Pulm Pharmacol. 1988;1(1):59-61.
117. Lichtenstein LM, Bochner BS. The role of basophils in asthma. Ann N Y Acad Sci. 1991;629:48-61.
118. Boyce JA, Broide D, Matsumoto K, Bochner BS. Advances in mechanisms of asthma, allergy, and immunology in 2008. J Allergy Clin Immunol. 2009 Mar;123(3):569-74.
119. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol. 2001 Mar;107(3):429-40.
120. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med. 1975 May 29;292(22):1152-5.
121. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990 Oct 11;323(15):1033-9.
122. Frew AJ, Kay AB. Eosinophils and T-lymphocytes in late-phase allergic reactions. J Allergy Clin Immunol. 1990 Mar;85(3):533-9.
123. Morjaria JB, Gnanakumaran G, Babu KS. Anti-IgE in allergic asthma and rhinitis: An update. Expert Opin Biol Ther. 2007 Nov;7(11):1739-47.
124. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 2001 Aug;108(2 Suppl):S65-71.
125. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997 Jun;155(6):1828-34.
126. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti- IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997 Jun;155(6):1835-40.
127. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006 Apr 19;(2)(2):CD003559.
128. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, 1304 Study Group. Efficacy and safety of omalizumab in an asian population with moderateto- severe persistent asthma. Respirology. 2009 Nov;14(8):1156-65.
129. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009 Dec;124(6):1210-6.
130. Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Clin Pediatr (Phila). 2009 Oct;48(8):859-65.
131. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994 May;10(5):471-80.
132. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992 May;89(5):958-67.
133. Ying S, Robinson DS, Varney V, Meng Q, Tsicopoulos A, Moqbel R, et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy. 1991 Nov;21(6):745-50.
134. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005 Dec;60(12):1012-8.
135. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006 Feb 16;354(7):697-708.
136. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995 Jul;152(1):76-80.
137. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax. 2002 Sep;57(9):774-8.
138. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alphamediated enhancement of T cell responses. J Immunol. 1987 Mar 15;138(6):1786-90.
139. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med. 1990 Jun 1;171(6):2025-41.
140. Huber M, Beutler B, Keppler D. Tumor necrosis factor alpha stimulates leukotriene production in vivo. Eur J Immunol. 1988 Dec;18(12):2085-8.
141. Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol. 1995 May 15;154(10):5411-7.
142. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med. 2006 Oct 1;174(7):753-62.
143. Rouhani FN, Meitin CA, Kaler M, Miskinis- Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergenmediated asthmatic airway inflammation. Respir Med. 2005 Sep;99(9):1175-82.
144. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: A double blind, randomised, placebo controlled trial. Thorax. 2008 Jul;63(7):584-91.
145. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al. A randomized, doubleblind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58.
146. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 May 1;175(9):926-34.
147. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275-85.
148. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002 Dec;46(12):3151-8.
149. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010 Aug;62(8):2517-24.
150. Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des. 2004;10(9):951-66.
151. Kobayashi S, Somlyo AV, Somlyo AP. Heparin inhibits the inositol 1,4,5-trisphosphate-dependent, but not the independent, calcium release induced by guanine nucleotide in vascular smooth muscle. Biochem Biophys Res Commun. 1988 Jun 16;153(2):625-31.
152. Ghosh TK, Eis PS, Mullaney JM, Ebert CL, Gill DL. Competitive, reversible, and potent antagonism of inositol 1,4,5-trisphosphate-activated calcium release by heparin. J Biol Chem. 1988 Aug 15;263(23):11075-9.
153. Tones MA, Bootman MD, Higgins BF, Lane DA, Pay GF, Lindahl U. The effect of heparin on the inositol 1,4,5-trisphosphate receptor in rat liver microsomes. dependence on sulphate content and chain length. FEBS Lett. 1989 Jul 31;252(1-2):105-8.
154. Worley PF, Baraban JM, Supattapone S, Wilson VS, Snyder SH. Characterization of inositol trisphosphate receptor binding in brain. regulation by pH and calcium. J Biol Chem. 1987 Sep 5;262(25):12132-6.
155. Ahmed T, Abraham WM, D'Brot J. Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis. 1992 Mar;145(3):566-70.
156. Ahmed T, Syriste T, Lucio J, Abraham W, Robinson M, D'Brot J. Inhibition of antigeninduced airway and cutaneous responses by heparin: A pharmacodynamic study. J Appl Physiol. 1993 Apr;74(4):1492-8.
157. Abraham WM, Abraham MK, Ahmed T. Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vitro. Int Arch Allergy Immunol. 1996 May;110(1):79-84.
158. Lucio J, D'Brot J, Guo CB, Abraham WM, Lichtenstein LM, Kagey-Sobotka A, et al. Immunologic mast cell-mediated responses andhistamine release are attenuated by heparin. J Appl Physiol. 1992 Sep;73(3):1093-101.
159. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis. 1993 Jan;147(1):160-3.
160. BOYLE JP, SMART RH, SHIREY JK. Heparin in the treatment of chronic obstructive bronchopulmonary disease. Am J Cardiol. 1964 Jul;14:25-8.
161. Fine NL, Shim C, Williams MH, Jr. Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis. 1968 Nov;98(5):886-7.
162. Bardana EJ, Jr, Edwards MJ, Pirofsky B. Heparin as treatment for bronchospasm of asthma. Ann Allergy. 1969 Mar;27(3):108-13.
163. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med. 1993 Jul 8;329(2):90-5.
164. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exerciseinduced asthma. Am J Respir Crit Care Med. 1996 May;153(5):1702-7.
165. Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med. 1999 Aug;160(2):576-81.
166. Ceyhan B, Celikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest. 1995 Apr;107(4):1009-12.
167. Pavord I, Mudassar T, Bennett J, Wilding P, Knox A. The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Eur Respir J. 1996 Feb;9(2):217-9.
168. Kalpaklioglu AF, Demirel YS, Saryal S, Misirligil Z. Effect of pretreatment with heparin on pulmonary and cutaneous response. J Asthma. 1997;34(4):337-43.
169. Bendstrup KE, Jensen JI. Inhaled heparin is effective in exacerbations of asthma. Respir Med. 2000 Feb;94(2):174-5.
170. Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J. Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9.
171. Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991;41 Suppl 3:14-22.
172. Elwood W, Lotvall JO, Barnes PJ, Chung KF. Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways. Am Rev Respir Dis. 1991 Jun;143(6):1340-4.
173. Knox AJ, Ajao P. Effect of frusemide on airway smooth muscle contractility in vitro. Thorax. 1990 Nov;45(11):856-9.
174. Perkins RS, Dent G, Chung KF, Barnes PJ. The effect of anion transport inhibitors and extracellular cl- concentration on eosinophil respiratory burst activity. Biochem Pharmacol. 1992 Jun 9;43(11):2480-3.
175. Bianco S, Vaghi A, Robuschi M, Refini RM, Pieroni MG, Sestini P. Steroid-sparing effect of inhaled lysine acetylsalicylate and furosemide in high-dose beclomethasone-dependent asthma. J Allergy Clin Immunol. 1995 May;95(5 Pt 1):937-43.
176. Bianco S, Pieroni MG, Refini RM, Robuschi M, Vaghi A, Sestini P. Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J. 1993 Jan;6(1):130-4.
177. Karpel JP, Dworkin F, Hager D, Feliciano S, Shapiro D, Posner L, et al. Inhaled furosemide is not effective in acute asthma. Chest. 1994 Nov;106(5):1396-400.
178. Ono Y, Kondo T, Tanigaki T, Ohta Y. Furosemide given by inhalation ameliorates acute exacerbation of asthma. J Asthma. 1997;34(4):283-9.
179. Pendino JC, Nannini LJ, Chapman KR, Slutsky A, Molfino NA. Effect of inhaled furosemide in acute asthma. J Asthma. 1998;35(1):89-93.
180. Tanigaki T, Kondo T, Hayashi Y, Katoh H, Kamio K, Urano T, et al. Rapid response to inhaled frusemide in severe acute asthma with hypercapnia. Respiration. 1997;64(1):108-10.
181. Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: Outcome of a systematic evaluation protocol. Thorax. 2003 Jul;58(7):561-6.